United Therapeutics Corp’s recent filing unveils that its PRESIDENT AND COO BENKOWITZ MICHAEL unloaded Company’s shares for reported $3.65 million on Jan 13 ’25. In the deal valued at $364.62 per share,10,000 shares were sold. As a result of this transaction, BENKOWITZ MICHAEL now holds 0 shares worth roughly $0.0.
Then, PATUSKY CHRISTOPHER sold 5,000 shares, generating $1,808,072 in total proceeds. Upon selling the shares at $361.61, the Director now owns 900 shares.
Before that, Michael Benkowitz bought 40,000 shares. United Therapeutics Corp shares valued at $14,598,800 were divested by the Officer at a price of $364.97 per share.
Morgan Stanley downgraded its United Therapeutics Corp [UTHR] rating to an Equal-weight from a an Overweight in a research note published on July 11, 2024; the price target was increased to $321 from $310. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Neutral”. Leerink Partners began covering UTHR with “an Outperform” recommendation on February 05, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated UTHR as “an Overweight”.
Price Performance Review of UTHR
On Tuesday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock jump 2.52% to $367.97. Over the last five days, the stock has gained 1.40%. United Therapeutics Corp shares have risen nearly 4.29% since the year began. Nevertheless, the stocks have risen 67.94% over the past one year. While a 52-week high of $417.82 was reached on 01/17/25, a 52-week low of $208.62 was recorded on 01/02/25. SMA at 50 days reached $369.79, while 200 days put it at $327.39.
Levels Of Support And Resistance For UTHR Stock
The 24-hour chart illustrates a support level at 362.34, which if violated will result in even more drops to 356.70. On the upside, there is a resistance level at 371.73. A further resistance level may holdings at 375.48. The Relative Strength Index (RSI) on the 14-day chart is 53.51, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.08, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 20.41%. Stochastics %K at 51.44% indicates the stock is a holding.
How much short interest is there in United Therapeutics Corp?
A steep rise in short interest was recorded in United Therapeutics Corp stocks on 2024-12-31, dropping by -0.16 million shares to a total of 1.92 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 2.08 million shares. There was a decline of -8.35%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 06, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $320 price target.
